Abstract
A hospital-based drug information system has been used to investigate a suspicion linking unexpected death with the administration of the tricyclic antidepressant, amitriptyline, in patients with a diagnosis of cardiac disease. 6 out of 53 patients with cardiac disease who were identified by the system died suddenly and unexpectedly after administration of the drug, compared with none of 53 control patients matched for sex, age, diagnosis, and length of stay in hospital. This high frequency of unexpected death was not found in patients receiving imipramine, nor in patients without cardiac disease receiving amitriptyline. Amitriptyline should be used with caution in patients with cardiac disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
